INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 212 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2019. The put-call ratio across all filers is 1.87 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $24,000 | +500.0% | 190 | +280.0% | 0.00% | – |
Q2 2019 | $4,000 | -33.3% | 50 | 0.0% | 0.00% | – |
Q1 2019 | $6,000 | +20.0% | 50 | 0.0% | 0.00% | – |
Q4 2018 | $5,000 | -16.7% | 50 | 0.0% | 0.00% | – |
Q3 2018 | $6,000 | +50.0% | 50 | 0.0% | 0.00% | – |
Q2 2018 | $4,000 | +33.3% | 50 | 0.0% | 0.00% | – |
Q1 2018 | $3,000 | 0.0% | 50 | 0.0% | 0.00% | – |
Q4 2017 | $3,000 | 0.0% | 50 | 0.0% | 0.00% | – |
Q3 2017 | $3,000 | -50.0% | 50 | 0.0% | 0.00% | – |
Q2 2017 | $6,000 | 0.0% | 50 | 0.0% | 0.00% | – |
Q1 2017 | $6,000 | +20.0% | 50 | 0.0% | 0.00% | – |
Q4 2016 | $5,000 | -37.5% | 50 | 0.0% | 0.00% | – |
Q3 2016 | $8,000 | +14.3% | 50 | 0.0% | 0.00% | – |
Q2 2016 | $7,000 | -50.0% | 50 | 0.0% | 0.00% | – |
Q1 2016 | $14,000 | +100.0% | 50 | 0.0% | 0.00% | – |
Q4 2015 | $7,000 | -12.5% | 50 | 0.0% | 0.00% | – |
Q3 2015 | $8,000 | -33.3% | 50 | 0.0% | 0.00% | – |
Q2 2015 | $12,000 | -14.3% | 50 | 0.0% | 0.00% | – |
Q1 2015 | $14,000 | +75.0% | 50 | 0.0% | 0.00% | – |
Q4 2014 | $8,000 | – | 50 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |